PMID- 29029545
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 39
DP  - 2017 Sep 12
TI  - The role of toll-like receptor 4 in tumor microenvironment.
PG  - 66656-66667
LID - 10.18632/oncotarget.19105 [doi]
AB  - Tumors are closely related to chronic inflammation, during which there are 
      various changes in inflammatory sites, such as immune cells infiltration, 
      pro-inflammation cytokines production, and interaction between immune cells and 
      tissue cells. Besides, substances, released from both tissue cells attacked by 
      exogenous etiologies, also act on local cells. These changes induce a dynamic and 
      complex microenvironment favorable for tumor growth, invasion, and metastasis. 
      The toll-like receptor 4 (TLR4) is the first identified member of the toll-like 
      receptor family that can recognize pathogen-associated molecular patterns (PAMPs) 
      and damage-associated molecular pattern (DAMPs). TLR4 expresses not only on 
      immune cells but also on tumor cells. Accumulating evidences demonstrated that 
      the activation of TLR4 in tumor microenvironment can not only boost the 
      anti-tumor immunity but also give rise to immune surveillance and tumor 
      progression. This review will summarize the expression and function of TLR4 on 
      dendritic cells (DCs), tumor-associated macrophages (TAMs), T cells, 
      myeloid-derived suppressor cells (MDSCs), tumor cells as well as stromal cells in 
      tumor microenvironment. Validation of the multiple role of TLR4 in tumors could 
      primarily pave the road for the development of anti-tumor immunotherapy.
FAU - Li, Jing
AU  - Li J
AD  - Department of Immunology, Tianjin Medical University Cancer Institute and 
      Hospital, Tianjin, China.
AD  - Department of Biotherapy, Tianjin Medical University Cancer Institute and 
      Hospital, Tianjin, China.
AD  - National Clinical Research Center for Cancer, Tianjin, China.
AD  - Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
AD  - Tianjin's Clinical Research Center for Cancer, Tianjin, China.
FAU - Yang, Fan
AU  - Yang F
AD  - Department of Biotherapy, Tianjin Medical University Cancer Institute and 
      Hospital, Tianjin, China.
AD  - National Clinical Research Center for Cancer, Tianjin, China.
AD  - Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
AD  - Tianjin's Clinical Research Center for Cancer, Tianjin, China.
AD  - Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
FAU - Wei, Feng
AU  - Wei F
AD  - Department of Immunology, Tianjin Medical University Cancer Institute and 
      Hospital, Tianjin, China.
AD  - National Clinical Research Center for Cancer, Tianjin, China.
AD  - Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
AD  - Tianjin's Clinical Research Center for Cancer, Tianjin, China.
AD  - Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
FAU - Ren, Xiubao
AU  - Ren X
AD  - Department of Immunology, Tianjin Medical University Cancer Institute and 
      Hospital, Tianjin, China.
AD  - Department of Biotherapy, Tianjin Medical University Cancer Institute and 
      Hospital, Tianjin, China.
AD  - National Clinical Research Center for Cancer, Tianjin, China.
AD  - Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
AD  - Tianjin's Clinical Research Center for Cancer, Tianjin, China.
AD  - Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170708
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5630445
OTO - NOTNLM
OT  - TLR4
OT  - immune cells
OT  - tumor cells
OT  - tumor microenvironment
COIS- CONFLICTS OF INTEREST No conflicts of interest exists in the submission of this 
      manuscript, and manuscript is approved by all authors for publication.
EDAT- 2017/10/17 06:00
MHDA- 2017/10/17 06:01
PMCR- 2017/09/12
CRDT- 2017/10/15 06:00
PHST- 2016/11/24 00:00 [received]
PHST- 2017/06/27 00:00 [accepted]
PHST- 2017/10/15 06:00 [entrez]
PHST- 2017/10/17 06:00 [pubmed]
PHST- 2017/10/17 06:01 [medline]
PHST- 2017/09/12 00:00 [pmc-release]
AID - 19105 [pii]
AID - 10.18632/oncotarget.19105 [doi]
PST - epublish
SO  - Oncotarget. 2017 Jul 8;8(39):66656-66667. doi: 10.18632/oncotarget.19105. 
      eCollection 2017 Sep 12.